greeksoup/ stock research

Pfizer (PFE) Q1 FY2025 earnings: revenue $13.7 billion, down 7.8% on the year

Pfizer Inc. (PFE) reported revenue of $13.7 billion for Q1 FY2025, the quarter ended 30 March 2025, down 7.8% on the same quarter a year earlier. Net income was $3.0 billion, down 4.8% on the year, and diluted earnings per share $0.52. The figures are the company's own, from the 10-Q it filed with the SEC on 5 May 2025.

Revenue
$13.7 billion
-7.8% on the year · -22.8% on the quarter
Q2 FY2023Q1 FY2025
Operating margin
n/a
Q2 FY2023Q1 FY2025
Net income
$3.0 billion
-4.8% on the year · +623.7% on the quarter
Q2 FY2023Q1 FY2025
Diluted EPS
$0.52
-5.5% on the year · +642.9% on the quarter
Q2 FY2023Q1 FY2025

this quarterthe same quarter a year earlierHover a bar for its figure.

Income statement (profit and loss)

$ millionQ1 FY2025Q4 FY2024Q1 FY2024On the quarterOn the yearLast 8 quarters
Revenue13,71517,76314,879-22.8%-7.8%
Cost of revenue2,8455,9093,379-51.9%-15.8%
Gross profit10,87011,85411,500-8.3%-5.5%
Gross margin79.3%66.7%77.3%
Research and development2,2033,0352,493-27.4%-11.6%
Selling, general and administrative3,0314,2743,495-29.1%-13.3%
Interest expense654740790-11.6%-17.2%
Pre-tax income2,785-10.03,421-18.6%
Income tax-189-421293
Effective tax rate-6.8%n/a8.6%
Net income2,9674103,115+623.7%-4.8%
Net margin21.6%2.3%20.9%
Diluted EPS$0.52$0.07$0.55+642.9%-5.5%
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionQ1 FY2025Q4 FY2024Q1 FY2024On the quarterOn the yearLast 8 quarters
Operating cash flow2,3356,7211,090-65.3%+114.2%
Capital expenditure564917704-38.5%-19.9%
Free cash flow1,7715,804386-69.5%+358.8%
Free cash flow margin12.9%32.7%2.6%
Cash from investing3,274-1,6231,732+89.0%
Cash from financing-5,227-5,114-4,931
Depreciation and amortisation1,6181,7921,736-9.7%-6.8%
Share-based compensation170177220-4.0%-22.7%
Dividends paid2,4372,3802,372+2.4%+2.7%
Dividend per share$0.00n/a$0.00
Diluted shares, weighted5,710m5,703m5,697m+0.1%+0.2%
Shares outstanding at period end5,685m5,667m5,667m+0.3%+0.3%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ1 FY2025Q4 FY2024Q1 FY2024On the quarterOn the yearLast 8 quarters
Shareholders' equity90,33888,20392,282+2.4%-2.1%
Non-controlling interest299294276+1.7%+8.3%
Debt62,10964,35169,539-3.5%-10.7%
Operating lease liabilitiesn/a2,286n/a
Other liabilities55,28258,26258,998-5.1%-6.3%
Total liabilities and equity208,028213,396221,095-2.5%-5.9%
Fixed assets18,34718,39318,803-0.3%-2.4%
Goodwill68,44468,52769,297-0.1%-1.2%
Intangible assets53,97655,41162,829-2.6%-14.1%
Investments15,96613,10919,830+21.8%-19.5%
Cash and equivalents1,4301,043719+37.1%+98.9%
Receivables11,84511,46310,989+3.3%+7.8%
Inventory10,85210,85110,892+0.0%-0.4%
Other assets27,16834,59927,736-21.5%-2.0%
Total assets208,028213,396221,095-2.5%-5.9%

Questions

What was Pfizer's revenue in Q1 FY2025?

Pfizer (PFE) reported revenue of $13.7 billion for Q1 FY2025, the quarter ended 30 March 2025, down 7.8% on the same quarter a year earlier.

How much did Pfizer earn in Q1 FY2025?

Net income for Q1 FY2025 was $3.0 billion, down 4.8% on the year, and diluted earnings per share $0.52.

When did Pfizer report Q1 FY2025 results?

Pfizer filed its 10-Q for the quarter ended 30 March 2025 with the SEC on 5 May 2025.

Quarterly results, the last 20 quarters

Q4 FY2021 * †Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023 †Q2 FY2023 †Q3 FY2023 †Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue23,63525,66127,74222,63824,28918,48613,00713,49114,24814,87913,28317,70217,76313,71514,65316,65417,55714,45115,03416,583
Cost of revenue9,7369,9848,6486,0639,6494,8863,2379,2697,5623,3793,3005,2635,9092,8453,7784,1725,2723,5484,0924,028
Gross profit13,89915,67719,09416,57514,64013,6009,7704,2226,68611,5009,98312,43911,85410,87010,87512,48212,28510,90310,94212,555
Gross margin59%61%69%73%60%74%75%31%47%77%75%70%67%79%74%75%70%75%73%76%
R&D5,9092,3012,8152,6963,6162,5052,6482,7112,8152,4932,6962,5983,0352,2032,4822,5463,2062,4902,8093,016
SG&A4,0992,5933,0483,3914,6453,4183,4973,2814,5753,4953,7173,2444,2743,0313,4153,1864,1622,9613,4113,279
Interest expense314322293311312318508695688790778783740654654652711668667662
Pre-tax income3,8439,05011,4479,0015,2316,2702,269-3,352-4,1293,421-1034,715-10.02,7853,0443,334-1,6433,170-6533,385
Tax rate6%13%14%4%4%11%-3%n/an/a9%n/a5%n/a-7%5%-6%n/a15%n/a4%
Net income3,3937,8649,9068,6084,9945,5432,327-2,382-3,3693,11541.04,4654102,9672,9103,541-1,6472,687-2483,242
Net margin14%31%36%38%21%30%18%-18%-24%21%0%25%2%22%20%21%-9%19%-2%20%
Diluted EPS$0.59$1.37$1.73$1.51$0.87$0.97$0.41-$0.42-$0.60$0.55$0.01$0.78$0.07$0.52$0.51$0.62-$0.29$0.47-$0.04$0.56
Operating cash flow5,9146,5418,1705,9748,5821,212-1,2083,4565,2401,090-1,7816,7146,7212,335-5824,6035,3482,6158355,375
Capital expenditure9936437518411,0011,1399148101,044704637651917564618602845436533573
Free cash flow4,9215,8987,4195,1337,58173.0-2,1222,6464,196386-2,4186,0635,8041,771-1,2004,0014,5032,1793024,802
Buybacks0.02,0000.00.00.00.00.00.00.0n/an/an/an/an/an/an/an/an/an/an/a
Dividends paid2,1892,2492,2442,2452,2452,3032,3152,3142,3152,3722,3802,3802,3802,4372,4452,4442,4452,4452,4512,451
Shares outstanding5,619m5,645m5,646m5,646m5,619m5,645m5,646m5,646m5,647m5,667m5,667m5,667m5,667m5,685m5,686m5,686m5,686m5,699m5,700m5,700m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 March 2025, filed 5 May 2025: the filing.